Skip to content
Top Menu
  • Log In
  • Register
  • Facebook
  • Twitter
  • LinkedIn
MyChesCo

MyChesCo

Chester County News and Community Website

  • Communities
    • Avondale
    • Berwyn
    • Coatesville
    • Cochranville
    • Devon
    • Downingtown
    • Exton
    • Honey Brook
    • Kennett Square
    • Malvern
    • Oxford
    • Paoli
    • Parkesburg
    • Phoenixville
    • Spring City
    • Toughkenamon
    • West Chester
    • West Grove
  • Education
    • Chester County Intermediate Unit
    • School Districts
      • Avon Grove School District
      • Coatesville Area School District
      • Downingtown Area School District
      • Great Valley School District
      • Kennett Consolidated School District
      • Octorara Area School District
      • Owen J. Roberts School District
      • Oxford Area School District
      • Phoenixville Area School District
      • Spring-Ford Area School District
      • Tredyffrin-Easttown School District
      • Twin Valley School District
      • Unionville-Chadds Ford School District
      • West Chester Area School District
    • Charter Schools
    • Independent Schools
    • Colleges and Universities
    • Chester County Library System
  • News
    • Traffic
    • Weather
    • Business
    • Health / Medical
    • National
    • Pennsylvania
    • Sports
  • Entertainment
  • Lifestyle
  • Tools
    • Members
    • Groups
    • Submit an Article
    • Contact Us
    • Signup for Newsletter
    • Contests and Giveaways
    • Gas Prices
    • Register
    • Log In
  • About
    • MyChesCo
    • Writing for Us
    • Advertising with Us
    • Contacting Us
    • Citizen Journalism
    • Submitting Articles
    • Starting a Group
    • How to Support Us
    • Terms of Service
    • Privacy Policy
    • DMCA Policy
    • AI Disclosure
  • Shop

Hypertension

Mineralys Therapeutics
Regional

Mineralys Therapeutics Publishes Phase 3 Trial Results in JAMA for Hypertension Treatment

July 1, 2025June 30, 2025 - by Timothy Alexander

RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced the publication of groundbreaking results from its pivotal Phase 3 Launch-HTN trial in the Journal of the American Medical Association …

Mineralys Therapeutics Publishes Phase 3 Trial Results in JAMA for Hypertension Treatment Read More

HemiClor
Regional

PRM Pharma Launches HEMICLOR, First FDA-Approved Low-Dose Chlorthalidone Tablet

June 26, 2025June 25, 2025 - by Timothy Alexander

WEST CONSHOHOCKEN, PA — PRM Pharma, LLC has announced the availability of HEMICLOR® (12.5 mg chlorthalidone tablets), the first FDA-approved low-dose formulation of chlorthalidone for the treatment of hypertension in …

PRM Pharma Launches HEMICLOR, First FDA-Approved Low-Dose Chlorthalidone Tablet Read More
Orchestra BioMed Holdings
Regional

Orchestra BioMed Highlights AVIM Therapy’s Potential at CSI 2025 Meeting

June 18, 2025June 18, 2025 - by Timothy Alexander

NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) has presented key clinical insights into its atrioventricular interval modulation (AVIM) therapy for high-risk hypertension during the Congenital, Structural, and …

Orchestra BioMed Highlights AVIM Therapy’s Potential at CSI 2025 Meeting Read More

Mineralys Therapeutics
Regional

Mineralys Therapeutics Reveals Promising Phase 3 Results for Hypertension Drug Lorundrostat

May 25, 2025May 24, 2025 - by Timothy Alexander

RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced detailed results from its pivotal Phase 3 Launch-HTN trial, showcasing the efficacy and safety of lorundrostat for patients with uncontrolled …

Mineralys Therapeutics Reveals Promising Phase 3 Results for Hypertension Drug Lorundrostat Read More
Mineralys Therapeutics
Regional

Mineralys Therapeutics to Present Phase 3 Data on Lorundrostat at European Hypertension Meeting

May 23, 2025May 22, 2025 - by Timothy Alexander

RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced that the findings from its pivotal Phase 3 Launch-HTN trial on lorundrostat, a novel medication targeting uncontrolled hypertension (uHTN) and …

Mineralys Therapeutics to Present Phase 3 Data on Lorundrostat at European Hypertension Meeting Read More

HemiClor
Regional

FDA Approves Low-Dose Hypertension Treatment HemiClor

May 12, 2025May 12, 2025 - by Timothy Alexander

WEST CONSHOHOCKEN, PA — The U.S. Food and Drug Administration (FDA) has approved HemiClor, a 12.5 mg chlorthalidone tablet developed by PRM Pharma, LLC, for the treatment of hypertension in …

FDA Approves Low-Dose Hypertension Treatment HemiClor Read More
Mineralys Therapeutics
Regional

Mineralys Therapeutics Publishes Pivotal Hypertension Trial Results in NEJM

April 28, 2025April 27, 2025 - by Timothy Alexander

RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) announced the publication of groundbreaking Phase 2 trial results for its medication lorundrostat in the New England Journal of Medicine (NEJM). The …

Mineralys Therapeutics Publishes Pivotal Hypertension Trial Results in NEJM Read More

Idorsia
Regional

New Hypertension Treatment TRYVIO Now Available in the U.S.

November 19, 2024November 18, 2024 - by Timothy Alexander

RADNOR, PA — Idorsia Pharmaceuticals U.S. Inc. has announced the availability of TRYVIOâ„¢ (aprocitentan) in the United States for adults suffering from hypertension. This new medication is intended to be used …

New Hypertension Treatment TRYVIO Now Available in the U.S. Read More
Mineralys Therapeutics
Regional

Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Pivotal Hypertension Trial

October 31, 2024October 30, 2024 - by Timothy Alexander

RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) announced the swift completion of participant enrollment in its Launch-HTN trial, a critical component of its pivotal program investigating lorundrostat for the …

Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Pivotal Hypertension Trial Read More
Mineralys Therapeutics
Regional

Mineralys Therapeutics to Host Virtual Event on Hypertension Treatment Advances

October 24, 2024October 22, 2024 - by Timothy Alexander

RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced an upcoming virtual Key Opinion Leader (KOL) event scheduled for Wednesday, October 30, 2024, at 10:00 AM ET. This event will …

Mineralys Therapeutics to Host Virtual Event on Hypertension Treatment Advances Read More

Posts pagination

1 2 Next

Trending News

  • Gwynedd Mercy University Launches Compassionate Care Collaborative to Tackle Healthcare Workforce Gaps

  • ARPA-H Launches Ambitious Program to Regenerate Brain Tissue and Restore Neurological Function

  • Teens Busted After Dawn Dunkin’ Heist in Bear — Cash Stolen, All Four Arrested

  • HHS Reverses Clinton-Era Policy, Restricts Federal Benefits to U.S. Citizens

  • Runaway Truck Smashes Sinking Spring Business, Sparks Gas Leak — Police Seek Help to Track Driver

Subscribe for Updates

Follow Us

  • Facebook
  • X
  • LinkedIn
  • Google
  • RSS Feed

Tools

  • Members
  • Newsletter
  • Events
  • Groups
  • Guest Articles
  • Coupon Center
  • Gas Prices
  • Log In
  • Register

About Us

  • About MyChesCo
  • Advertise
  • Contact Us
  • Support Us
  • Write for Us
  • Terms of Service
  • Privacy Policy
  • DMCA Policy
  • Affiliate Disclaimer

Recommended Reading

Arrested

Teens Busted After Dawn Dunkin’ Heist in Bear — Cash Stolen, All Four Arrested

July 14, 2025July 14, 2025

US Department of Health and Human Services (HHS)

HHS Reverses Clinton-Era Policy, Restricts Federal Benefits to U.S. Citizens

July 14, 2025July 13, 2025

Ryder truck

Runaway Truck Smashes Sinking Spring Business, Sparks Gas Leak — Police Seek Help to Track Driver

July 14, 2025July 14, 2025

Copyright © 2025 MyChesCo.